Darzalex 100 mg

DARZALEX 100 MG is a solution for intravenous use, containing the active ingredient daratumumab. This medication is commonly used in the management of certain hematologic conditions. It is manufactured by Janssen Inc. in Canada.

DARZALEX 100 MG is primarily used in the treatment of specific types of blood cancers. Daratumumab, the active ingredient, is a monoclonal antibody that targets certain proteins on the surface of cancer cells. This medication is often prescribed as part of a comprehensive treatment plan for conditions like multiple myeloma. Patients should consult their healthcare provider to understand what is DARZALEX used for in their specific case.

Common effects of DARZALEX 100 MG may include infusion-related reactions, such as fever, chills, and shortness of breath. Other potential effects include fatigue, nausea, and upper respiratory tract infections. These effects can vary from person to person, and not everyone will experience them. It is important to discuss any concerns with a healthcare professional.

DARZALEX 100 MG should be handled with care and administered by a healthcare professional. It is crucial to follow the prescribed dosage and administration instructions. Patients with a history of severe allergic reactions or certain medical conditions should inform their healthcare provider before starting this medication. Proper storage and handling are essential to maintain the integrity of the solution.

DARZALEX 100 MG may interact with other medications, including those that affect the immune system. It is important to inform your healthcare provider about all medications you are taking, including over-the-counter drugs and supplements. Alcohol and certain foods may also interact with this medication, so it is advisable to discuss any dietary restrictions with your healthcare provider.